Months after the latest losartan recall and more than a year after drug companies first started pulling bulk lots of angiotensin II receptor blockers (ARB) from pharmacy shelves, the FDA has issued a statement updating the American public on the scope of the situation.
An editorial published in the latest issue of The Lancet suggests physicians might make quicker progress toward reducing global levels of uncontrolled hypertension if they reframe the condition as part of a patient’s whole health profile, rather than as an isolated disease.
Rates of hypertension have been climbing in the U.S. in recent years, according to an analysis by Blue Cross Blue Shield, and they’re growing fastest among millennials and adults in their mid-thirties and forties.
Intensive blood pressure control resulted in fewer white matter brain lesions than standard BP control in a recent study of nearly 450 hypertensive patients, suggesting stricter hypertension management could have significant benefits for brain health.
A study published in the New England Journal of Medicine July 18 suggests it may be time for the medical community to rethink its perception of diastolic blood pressure, which has long been considered inferior to systolic BP as a measure of cardiovascular wellness.
Massachusetts-based Azurity Pharmaceuticals announced July 10 it had received FDA approval for Katerzia Oral Suspension, making the drug the first and only FDA-approved amlodipine oral suspension to hit the commercial market.